-
Clinical Optometry
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Sudden unilateral visual loss as an initial presentation of chronic myelogenous leukemia
Other
(1954) Views (962) Full article downloads
Authors: Len V Hua, Salisa K Williams
Published Date March 2010
Volume 2010:2 Pages 29 - 35
DOI: http://dx.doi.org/10.2147/OPTO.S9449
Len V Hua, Salisa K Williams
Pacific University Eye Clinic, Forest Grove, OR, USA
Abstract: Leukemia is a cancer of the white blood cells. Many patients with leukemia are unaware of their disease until routine blood work up for other conditions reveals incidental findings leading to a diagnosis of leukemia. Up to 50% of patients with leukemia have ocular manifestations. In fact, floaters or decreased vision may be the initial symptom of leukemia.
Case study: A 51-year-old Caucasian female patient with sudden unilateral visual loss in the left eye was found to have bilateral retinal neovascularization and Roth spot hemorrhages. Blood work up and cytological analyses confirmed the Philadelphia chromosome, which has been implicated in the development of chronic myelogenous leukemia (CML). Further testing confirmed a diagnosis of chronic phase CML. After a two-month course of imatinib and close monitoring by a hematological oncologist, her vision has improved and the retinal vascularization has significantly resolved.
Conclusions: Eye care professionals are in a unique position to identify this devastating disease early on. A delay in diagnosis of the disease may lead to conversion into the acute phase, which has a poor prognosis for survival. A prompt referral to internal medicine and oncology for co-management is crucial.
Keywords: chronic myelogenous leukemia, retinal hemorrhages, Roth spot, imatinib (Gleevec®) Philadelphia chromosome, vision loss
Readers of this article also read:
Primary open angle glaucoma and hypothyroidism
Efficacy of hand held, inexpensive UV light sources on Acanthamoeba, causative organism in amoebic keratitis
A man with sudden loss of vision and ptosis
Intraocular eyelash after uneventful cataract surgery
Effect of customized near addition lenses on transient myopia induced by near-work
Sphenoethmoidal mucocele presenting with unilateral visual loss
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics
Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- A computer-based anaglyphic system for the treatment of amblyopia




